Mathematically engineered stromal cell–derived factor-1α stem cell cytokine analog enhances mechanical properties of infarcted myocardium

Abstract

The biomechanical response to a myocardial infarction consists of ventricular remodeling that leads to dilatation, loss of contractile function, abnormal stress patterns, and ultimately heart failure. We hypothesized that intramyocardial injection of our previously designed pro-angiogenic chemokine, an engineered stromal cell-derived factor-1α analog (ESA), improves mechanical properties of the heart after infarction. Male rats (n=54) underwent either sham surgery (n=17) with no coronary artery ligation or ligation of the left anterior descending artery (n=37). The rats in the myocardial infarction group were then randomized to receive either saline (0.1 mL, n=18) or ESA (6 μg/kg, n=19) injected into the myocardium at 4 predetermined spots around the border zone. Echocardiograms were performed preoperatively and before the terminal surgery. After 4 weeks, the hearts were explanted and longitudinally sectioned. Uniaxial tensile testing was completed using an Instron 5543 Microtester. Optical strain was evaluated using custom image acquisition software, Digi-Velpo, and analyzed in MATLAB. Compared with the saline control group at 4 weeks, the ESA-injected hearts had a greater ejection fraction (71.8% ± 9.0% vs 55.3% ± 12.6%, P=.0004), smaller end-diastolic left ventricular internal dimension (0.686 ± 0.110 cm vs 0.763 ± 0.160 cm, P=.04), greater cardiac output (36 ± 11.6 mL/min vs 26.9 ± 7.3 mL/min, P=.05), and a lower tensile modulus (251 ± 56 kPa vs 301 ± 81 kPa, P=.04). The tensile modulus for the sham group was 195 ± 56 kPa, indicating ESA injection results in a less stiff ventricle. Direct injection of ESA alters the biomechanical response to myocardial infarction, improving the mechanical properties in the postinfarct heart.